ACTRIMS 2022 | Characterizing real-world outcomes among COVID-19 vaccinated patients with MS

Namita Tundia, PhD, EMD Serono Inc., Billerica, MA, shares real-world evidence on relapse and health care resource utilization rates in patients with multiple sclerosis (MS) following COVID-19 vaccination. To characterize MS outcomes among vaccinated patients, 3 cohorts were investigated: patients treated with anti-CD20 therapies or S1P receptor modulators (Cohort 1), patients treated with other disease modifying therapies (Cohort 2), and untreated patients (Cohort 3). The retrospective analysis revealed greater relapse and health care resource utilization rates in Cohort 1, compared to Cohorts 2 and 3. Dr Tundia comments on the implications of these findings in a post-pandemic world. This interview took place at the ACTRIMS Forum 2022 in West Palm Beach, Florida.